Skip to main content

Advertisement

SpringerLink
Log in

Radiation therapy for oligometastatic non-small cell lung cancer

  • Published:
Cancer and Metastasis Reviews Aims and scope Submit manuscript

Abstract

Interest has been increasing in the treatment of non-small cell lung cancer (NSCLC) patients with limited or oligometastatic disease. Surgery has historically been used to remove non-small cell lung cancer metastases, but recent developments including advanced radiotherapy planning and delivery techniques, often called stereotactic body radiotherapy (SBRT) or stereotactic ablative radiotherapy (SABR), has been associated with high rates of treated metastasis control. Therefore, given common comorbid disease, often precluding surgery, an increasing number of oligometastatic NSCLC patients are receiving radiation for ablation of all disease. Early results have reported favorable survival for some, with improved median survival, and approximately 25 % alive long term. Patients with fewer metastases, those treated to all known cancerous sites, and longer disease-free intervals tend to have better outcomes. While promising, better clinical criteria are needed to optimize patient selection. The biologic underpinnings of the oligometastatic state are beginning to be demonstrated with specific microRNAs being associated with limited or no progression both in human samples and murine models. Clinical trials are ongoing to improve the techniques used to deliver radiotherapy for NSCLC oligometastases. Ideally, randomized studies will need to be conducted to demonstrate the utility of these treatments suggested by the uncontrolled studies to date. In lieu of these, data presented here may help guide clinicians as to appropriate patient selection.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Peters, S., Adjei, A. A., Gridelli, C., Reck, M., Kerr, K., Felip, E., et al. (2012). Metastatic non-small-cell lung cancer (NSCLC): ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 23(Suppl 7), vii56–vii64. doi:10.1093/annonc/mds226.

    Article  PubMed  Google Scholar 

  2. Scagliotti, G. V., Parikh, P., von Pawel, J., Biesma, B., Vansteenkiste, J., Manegold, C., et al. (2008). Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. Journal of Clinical Oncology, 26(21), 3543–3551. doi:10.1200/JCO.2007.15.0375.

    Article  CAS  PubMed  Google Scholar 

  3. Lima, A. B., Macedo, L. T., & Sasse, A. D. (2011). Addition of bevacizumab to chemotherapy in advanced non-small cell lung cancer: a systematic review and meta-analysis. PLoS One, 6(8), e22681. doi:10.1371/journal.pone.0022681.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  4. Soria, J. C., Mauguen, A., Reck, M., Sandler, A. B., Saijo, N., Johnson, D. H., et al. (2013). Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer. Annals of Oncology, 24(1), 20–30. doi:10.1093/annonc/mds590.

    Article  PubMed  Google Scholar 

  5. Mok, T. S., Wu, Y. L., Thongprasert, S., Yang, C. H., Chu, D. T., Saijo, N., et al. (2009). Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. New England Journal of Medicine, 361(10), 947–957. doi:10.1056/NEJMoa0810699.

    Article  CAS  PubMed  Google Scholar 

  6. Kwak, E. L., Bang, Y. J., Camidge, D. R., Shaw, A. T., Solomon, B., Maki, R. G., et al. (2010). Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. New England Journal of Medicine, 363(18), 1693–1703. doi:10.1056/NEJMoa1006448.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  7. Shaw, A. T., Ou, S. H., Bang, Y. J., Camidge, D. R., Solomon, B. J., Salgia, R., et al. (2014). Crizotinib in ROS1-rearranged non-small-cell lung cancer. New England Journal of Medicine. doi:10.1056/NEJMoa1406766.

    Google Scholar 

  8. Patchell, R. A., Tibbs, P. A., Walsh, J. W., Dempsey, R. J., Maruyama, Y., Kryscio, R. J., et al. (1990). A randomized trial of surgery in the treatment of single metastases to the brain. New England Journal of Medicine, 322(8), 494–500.

    Article  CAS  PubMed  Google Scholar 

  9. Kocher, M., Soffietti, R., Abacioglu, U., Villa, S., Fauchon, F., Baumert, B. G., et al. (2011). Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952–26001 study. Journal of Clinical Oncology, 29(2), 134–141. doi:10.1200/JCO.2010.30.1655.

    Article  PubMed Central  PubMed  Google Scholar 

  10. Andrews, D. W., Scott, C. B., Sperduto, P. W., Flanders, A. E., Gaspar, L. E., Schell, M. C., et al. (2004). Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet, 363(9422), 1665–1672.

    Article  PubMed  Google Scholar 

  11. Patel, P. R., Yoo, D. S., Niibe, Y., Urbanic, J. J., & Salama, J. K. (2012). A call for the aggressive treatment of oligometastatic and oligo-recurrent non-small cell lung cancer. Pulmonary Medicine, 2012, 480961. doi:10.1155/2012/480961.

    Article  PubMed Central  PubMed  Google Scholar 

  12. Lewis, SL., Porceddu, S., Nakamura, N., Palma, D., Lo, S., Hoskin, P., et al. (2014). Definitive stereotactic body radiotherapy (SBRT) for extracranial oligometastases: an international survey of >1000 Radiation Oncologists. American Journal of Clinical Oncology. doi:10.1097/COC.0000000000000169.

  13. Hellman, S., & Weichselbaum, R. R. (1995). Oligometastases. Journal of Clinical Oncology, 13(1), 8–10.

    CAS  PubMed  Google Scholar 

  14. Rubin, P., & Green, J. (1968). Solitary metastases. Springfield, IL: C. C. Thomas.

    Google Scholar 

  15. Cheruvu, P., Metcalfe, S. K., Metcalfe, J., Chen, Y., Okunieff, P., & Milano, M. T. (2011). Comparison of outcomes in patients with stage III versus limited stage IV non-small cell lung cancer. [Comparative Study]. Radiation Oncology, 6, 80. doi:10.1186/1748-717X-6-80.

    Article  PubMed Central  PubMed  Google Scholar 

  16. Albain, K. S., Crowley, J. J., LeBlanc, M., & Livingston, R. B. (1991). Survival determinants in extensive-stage non-small-cell lung cancer: the Southwest Oncology Group experience. Journal of Clinical Oncology, 9(9), 1618–1626.

    CAS  PubMed  Google Scholar 

  17. Torok, J., Kelsey, C. R., & Salama, J. K. Patterns of Distant Metastases in Surgically Managed Early Stage Non-Small Cell Lung Cancer. In 55th Annual ASTRO Meeting., Atlanta, Georgia., September 22–25, 2013 2013

  18. Hasselle, M. D., Haraf, D. J., Rusthoven, K. E., Golden, D. W., Salgia, R., Villaflor, V. M., et al. (2012). Hypofractionated image-guided radiation therapy for patients with limited volume metastatic non-small cell lung cancer. [Research Support, Non-U.S. Gov’t]. Journal of Thoracic Oncology, 7(2), 376–381. doi:10.1097/JTO.0b013e31824166a5.

    Article  PubMed  Google Scholar 

  19. Fong, Y., Fortner, J., Sun, R. L., Brennan, M. F., & Blumgart, L. H. (1999). Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Annals of Surgery, 230(3), 309–318. discussion 318–321.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  20. Lussier, Y. A., Khodarev, N. N., Regan, K., Corbin, K., Li, H., Ganai, S., et al. (2012). Oligo- and polymetastatic progression in lung metastasis(es) patients is associated with specific microRNAs. PLoS One, 7(12), e50141. doi:10.1371/journal.pone.0050141.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  21. Lussier, Y. A., Xing, H. R., Salama, J. K., Khodarev, N. N., Huang, Y., Zhang, Q., et al. (2011). MicroRNA expression characterizes oligometastasis(es). PLoS One, 6(12), e28650. doi:10.1371/journal.pone.0028650.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  22. Niibe, Y., & Hayakawa, K. (2010). Oligometastases and oligo-recurrence: the new era of cancer therapy. Japanese Journal of Clinical Oncology, 40(2), 107–111. doi:10.1093/jjco/hyp167.

    Article  PubMed Central  PubMed  Google Scholar 

  23. Gan, G. N., Weickhardt, A. J., Scheier, B., Doebele, R. C., Gaspar, L. E., Kavanagh, B. D., et al. (2014). Stereotactic radiation therapy can safely and durably control sites of extra-central nervous system oligoprogressive disease in anaplastic lymphoma kinase-positive lung cancer patients receiving crizotinib. International Journal of Radiation Oncology, Biology, and Physics, 88(4), 892–898. doi:10.1016/j.ijrobp.2013.11.010.

    Article  Google Scholar 

  24. Mehta, N., Mauer, A. M., Hellman, S., Haraf, D. J., Cohen, E. E., Vokes, E. E., et al. (2004). Analysis of further disease progression in metastatic non-small cell lung cancer: implications for locoregional treatment. International Journal of Oncology, 25(6), 1677–1683.

    PubMed  Google Scholar 

  25. De Pas, T. M., de Braud, F., Catalano, G., Putzu, C., Veronesi, G., Leo, F., et al. (2007). Oligometastatic non-small cell lung cancer: a multidisciplinary approach in the positron emission tomographic scan era. Annals of Thoracic Surgery, 83(1), 231–234. doi:10.1016/j.athoracsur.2006.08.017.

    Article  PubMed  Google Scholar 

  26. Ung, Y., Gu, C., Cline, K., Sun, A., & MacRae, R. (2011). An Ontario Clinical Oncology Group (OCOG) randomized trial (PET START) of FDG PET/CT in patients with stage III non-small cell lung cancer (NSCLC): Predictors of overall survival. Journal of Clinical Oncology, 29((suppl; abstr 7018)).

  27. Yachida, S., Jones, S., Bozic, I., Antal, T., Leary, R., Fu, B., et al. (2010). Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature, 467(7319), 1114–1117. doi:10.1038/nature09515.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  28. Campbell, P. J., Yachida, S., Mudie, L. J., Stephens, P. J., Pleasance, E. D., Stebbings, L. A., et al. (2010). The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature, 467(7319), 1109–1113. doi:10.1038/nature09460.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  29. Weichselbaum, R. R., & Hellman, S. (2011). Oligometastases revisited. Nature Reviews. Clinical Oncology, 8(6), 378–382. doi:10.1038/nrclinonc.2011.44.

    CAS  PubMed  Google Scholar 

  30. Gupta, G. P., & Massague, J. (2006). Cancer metastasis: building a framework. Cell, 127(4), 679–695. doi:10.1016/j.cell.2006.11.001.

    Article  CAS  PubMed  Google Scholar 

  31. Kirkpatrick, J. P., Kelsey, C. R., Palta, M., Cabrera, A. R., Salama, J. K., Patel, P., et al. (2013). Stereotactic body radiotherapy: a critical review for non-radiation oncologists. Cancer. doi:10.1002/cncr.28515.

    PubMed  Google Scholar 

  32. Rusthoven, K. E., Kavanagh, B. D., Burri, S. H., Chen, C., Cardenes, H., Chidel, M. A., et al. (2009). Multi-institutional phase I/II trial of stereotactic body radiation therapy for lung metastases. Journal of Clinical Oncology, 27(10), 1579–1584.

    Article  PubMed  Google Scholar 

  33. Rusthoven, K. E., Kavanagh, B. D., Cardenes, H., Stieber, V. W., Burri, S. H., Feigenberg, S. J., et al. (2009). Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. Journal of Clinical Oncology, 27(10), 1572–1578. doi:10.1200/JCO.2008.19.6329.

    Article  PubMed  Google Scholar 

  34. Torok, J., Wegner, R. E., Burton, S. A., & Heron, D. E. (2011). Stereotactic body radiation therapy for adrenal metastases: a retrospective review of a noninvasive therapeutic strategy. [Case Reports Review]. Future Oncology, 7(1), 145–151. doi:10.2217/fon.10.165.

    Article  CAS  PubMed  Google Scholar 

  35. Rudra, S., Malik, R., Ranck, M. C., Farrey, K., Golden, D. W., Hasselle, M. D., et al. (2013). Stereotactic body radiation therapy for curative treatment of adrenal metastases. Technology in Cancer Research & Treatment, 12(3), 217–224. doi:10.7785/tcrt.2012.500320.

    CAS  Google Scholar 

  36. Milano, M. T., Katz, A. W., Zhang, H., & Okunieff, P. (2012). Oligometastases treated with stereotactic body radiotherapy: long-term follow-up of prospective study. International Journal of Radiation Oncology, Biology, and Physics, 83(3), 878–886. doi:10.1016/j.ijrobp.2011.08.036.

    Article  Google Scholar 

  37. Salama, J. K., Hasselle, M. D., Chmura, S. J., Malik, R., Mehta, N., Yenice, K. M., et al. (2012). Stereotactic body radiotherapy for multisite extracranial oligometastases: final report of a dose escalation trial in patients with 1 to 5 sites of metastatic disease. Cancer, 118(11), 2962–2970. doi:10.1002/cncr.26611.

    Article  PubMed  Google Scholar 

  38. Kao, J., Chen, C. T., Tong, C. C., Packer, S. H., Schwartz, M., Chen, S. H., et al. (2013). Concurrent sunitinib and stereotactic body radiotherapy for patients with oligometastases : final report of a prospective clinical trial. Targeted Oncology. doi:10.1007/s11523-013-0280-y.

    PubMed Central  PubMed  Google Scholar 

  39. Khan, A. J., Mehta, P. S., Zusag, T. W., Bonomi, P. D., Penfield Faber, L., Shott, S., et al. (2006). Long term disease-free survival resulting from combined modality management of patients presenting with oligometastatic, non-small cell lung carcinoma (NSCLC). Radiotherapy and Oncology, 81(2), 163–167.

    Article  PubMed  Google Scholar 

  40. De Ruysscher, D., Wanders, R., van Baardwijk, A., Dingemans, A. M., Reymen, B., Houben, R., et al. (2012). Radical treatment of non-small-cell lung cancer patients with synchronous oligometastases: long-term results of a prospective phase II trial (Nct01282450). Journal of Thoracic Oncology, 7(10), 1547–1555. doi:10.1097/JTO.0b013e318262caf6.

    Article  PubMed  Google Scholar 

  41. Ashworth, A. B., Senan, S., Palma, D. A., Riquet, M., Chan Ahn, Y., Ricardi, U., et al. (2014). An individual patient data metaanalysis of outcomes and prognostic factors after treatment of oligometastatic non-small-cell lung cancer. Clinical Lung Cancer. doi:10.1016/j.cllc.2014.04.003.

    PubMed  Google Scholar 

  42. McCammon, R., Schefter, T. E., Gaspar, L. E., Zaemisch, R., Gravdahl, D., & Kavanagh, B. (2009). Observation of a dose-control relationship for lung and liver tumors after stereotactic body radiation therapy. International Journal of Radiation Oncology, Biology, and Physics, 73(1), 112–118. doi:10.1016/j.ijrobp.2008.03.062.

    Article  Google Scholar 

  43. Corbin, K., Ranck, M., Hasselle, M., Golden, D., Partouche, J., Wu, T., et al. (2012). Feasibility and toxicity of hypofractionated image-guided radiotherapy for large volume limited metastatic disease. Practical Radiation Oncology, 3(4), 316–322. doi:10.1016/j.prro.2012.08.006.

  44. Solanki, A. A., Weichselbaum, R. R., Appelbaum, D., Farrey, K., Yenice, K. M., Chmura, S. J., et al. (2012). The utility of FDG-PET for assessing outcomes in oligometastatic cancer patients treated with stereotactic body radiotherapy: a cohort study. Radiation Oncology, 7, 216. doi:10.1186/1748-717X-7-216.

    Article  PubMed Central  PubMed  Google Scholar 

  45. Palma, D. A., Haasbeek, C. J., Rodrigues, G. B., Dahele, M., Lock, M., Yaremko, B., et al. (2012). Stereotactic ablative radiotherapy for comprehensive treatment of oligometastatic tumors (SABR-COMET): study protocol for a randomized phase II trial. BMC Cancer, 12, 305. doi:10.1186/1471-2407-12-305.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  46. Ashworth, A., Rodrigues, G., Boldt, G., & Palma, D. (2013). Is there an oligometastatic state in non-small cell lung cancer? A systematic review of the literature. [Research Support, Non-U.S. Gov’t]. Lung Cancer, 82(2), 197–203. doi:10.1016/j.lungcan.2013.07.026.

    Article  PubMed  Google Scholar 

  47. Parikh, R. B., Cronin, A. M., Kozono, D. E., Oxnard, G. R., Mak, R. H., Jackman, D. M., et al. (2014). Definitive primary therapy in patients presenting with oligometastatic non-small cell lung cancer. International Journal of Radiation Oncology, Biology, and Physics, 89(4), 880–887. doi:10.1016/j.ijrobp.2014.04.007.

    Article  Google Scholar 

  48. Lopez Guerra, J. L., Gomez, D., Zhuang, Y., Hong, D. S., Heymach, J. V., Swisher, S. G., et al. (2012). Prognostic impact of radiation therapy to the primary tumor in patients with non-small cell lung cancer and oligometastasis at diagnosis. International Journal of Radiation Oncology, Biology, and Physics, 84(1), e61–e67. doi:10.1016/j.ijrobp.2012.02.054.

    Article  Google Scholar 

  49. Ashworth, A. B., Senan, S., Palma, D. A., Riquet, M., Ahn, Y. C., Ricardi, U., et al. (2014). An individual patient data metaanalysis of outcomes and prognostic factors after treatment of oligometastatic non-small-cell lung cancer. Clinical Lung Cancer, 15(5), 346–355. doi:10.1016/j.cllc.2014.04.003.

    Article  PubMed  Google Scholar 

  50. Yano, T., Okamoto, T., Haro, A., Fukuyama, S., Yoshida, T., Kohno, M., et al. (2013). Local treatment of oligometastatic recurrence in patients with resected non-small cell lung cancer. Lung Cancer, 82(3), 431–435. doi:10.1016/j.lungcan.2013.08.006.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, Duke University, Box 3085, Durham, NC, 27710, USA

    Joseph K. Salama

  2. Department of Radiation Oncology, Mayo Clinic, Scottsdale, AZ, USA

    Steven E. Schild

Authors
  1. Joseph K. Salama
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Steven E. Schild
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Joseph K. Salama.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Salama, J.K., Schild, S.E. Radiation therapy for oligometastatic non-small cell lung cancer. Cancer Metastasis Rev 34, 183–193 (2015). https://doi.org/10.1007/s10555-015-9559-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10555-015-9559-z

Keywords

Search

Navigation